AUS
NZ
UK
CA
USA
IND
Cambium Bio Limited (ASX:CMB) has announced a placement of 2.1 million fully paid ordinary shares at AUD 0.48 each, aiming to raise approximately AUD 1.008 million. The funds will support the pivotal phase 3 clinical trial of Elate Ocular®—the company’s therapeutic candidate targeting moderate to severe dry eye disease. The shares are set to be issued on 29 July 2026 under the company’s 10% additional placement capacity pursuant to ASX Listing Rule 7.1A.
Key Points
- Cambium Bio Limited (CMB) is conducting a placement of 2.1 million fully paid ordinary shares
- Shares priced at AUD 0.48 each, with settlement expected on 29 July 2026
- Proceeds will fund the phase 3 clinical trial of Elate Ocular® for moderate to severe dry eye disease
- Placement utilizes 10% additional placement capacity under ASX Listing Rule 7.1A, requiring no shareholder approval
- New shares will rank equally with existing ordinary shares; placement is not underwritten
Capital Raise Approach and Share Placement Details
Cambium Bio Limited has chosen a placement method to efficiently raise capital aligned with its clinical development goals. The company will issue 2.1 million ordinary fully paid shares at AUD 0.48 per share, with the issue date scheduled for 29 July 2026. This approach facilitates prompt capital access to support the company’s strategic objectives.
The issued shares belong to Cambium Bio’s existing class of ordinary fully paid securities, ensuring equal ranking with current shares from the issue date. The placement proceeds without shareholder approval by leveraging the company’s additional 10% placement capacity under ASX Listing Rule 7.1A. Details on lead managers, brokers, or underwriting arrangements were not disclosed, and no voluntary escrow applies to these securities.
Allocation of Proceeds to Elate Ocular® Phase 3 Clinical Trial
Funds raised will be dedicated to financing the pivotal phase 3 clinical trial of Elate Ocular® in patients with moderate to severe dry eye disease—a significant unmet medical need globally. Progression to phase 3 marks a critical milestone in the drug development pathway, focusing on confirming efficacy, safety, and comparative performance against existing treatments.
Phase 3 trials typically involve larger patient populations and represent some of the most capital-intensive stages of clinical development. Cambium Bio’s commitment to funding this trial underscores its strategic focus on advancing Elate Ocular® through regulatory approval processes. No other uses of proceeds were disclosed, indicating a singular focus on this clinical advancement.
Compliance with ASX Listing Rule 7.1A and Placement Framework
The placement is conducted under Cambium Bio’s additional 10% placement capacity allowed by ASX Listing Rule 7.1A, enabling issuance of up to 10% of issued capital without shareholder approval, subject to regulatory conditions. All 2.1 million shares will be issued under this capacity.
Cambium Bio explained that this placement structure provides "efficient access to capital which meets the Company's capital raising purpose," opting against alternative methods such as pro rata entitlement offers or security purchase plans that would involve existing shareholders. The company confirmed no related party participation as defined by ASX Listing Rule 10.11, avoiding additional disclosure or approval requirements.
Clinical-Stage Development Focus and Market Positioning
Cambium Bio is a clinical-stage biopharmaceutical company focused on developing therapeutic solutions. Its lead asset, Elate Ocular®, targets moderate to severe dry eye disease, a prevalent ophthalmological condition with significant unmet treatment needs worldwide.
Advancing Elate Ocular® into phase 3 clinical trials highlights the company’s commitment to progressing its pipeline. Given the high capital demands of clinical development, equity placements like this are standard funding mechanisms for clinical-stage biopharmaceutical firms. Cambium Bio is registered under ABN 13 127 035 358 and listed on the ASX as CMB.
Issue Price and Shareholder Dilution Impact
The placement shares are priced at AUD 0.48 each. The company has not disclosed the current market price, total shares outstanding, or the discount/premium implied by the placement price, which are relevant for assessing dilution effects.
Issuing 2.1 million shares at this price will raise approximately AUD 1.008 million. The immediate impact on share price remains unclear due to lack of public data. Investors should be aware that new share issuances generally dilute existing shareholders’ ownership proportionally, with dilution magnitude dependent on total shares outstanding, which was not provided.
Regulatory Approvals and Secondary Market Sale Provisions
The placement requires no external approvals and is unconditional, indicating all necessary internal board and management approvals are in place. No regulatory hurdles beyond standard ASX notifications remain prior to settlement.
Regarding secondary market sales, Cambium Bio stated that any resale of these securities within 12 months will comply with secondary sale provisions under sections 707(3) and 1012C(6) of the Corporations Act, facilitated by a cleansing notice under sections 708A(5), 708AA(2)(f), 1012DA(5), or 1012DAA(2)(f). This allows resale without issuing a prospectus or product disclosure statement. The identities of placees and their intentions for secondary sales were not disclosed.
Dividend Policy and Future Capital Outlook
Cambium Bio confirmed no changes to its dividend or distribution policy will result from this placement. This aligns with typical clinical-stage biopharmaceutical companies’ practice of reinvesting capital into research, development, and clinical programs rather than paying dividends until profitability or significant revenue is achieved.
The capital raise for the phase 3 Elate Ocular® trial does not alter the company’s strategic capital allocation focus. No guidance was provided on future capital requirements, regulatory timelines, or commercial milestones related to Elate Ocular®.
Settlement Schedule and Market Execution
The 2.1 million shares are expected to settle and be issued on 29 July 2026. The announcement was made on 22 July 2026, approximately one week ahead of settlement, consistent with typical ASX Listing Rule 7.1A placement timelines that feature short notice and rapid settlement. No conditions precedent to settlement were disclosed.
Investment Highlights and Considerations
Key details for investors include the placement of 2.1 million shares at AUD 0.48 each, raising about AUD 1.008 million; issuance under ASX Listing Rule 7.1A without shareholder approval; settlement on 29 July 2026; and use of proceeds dedicated to funding the phase 3 clinical trial of Elate Ocular® for moderate to severe dry eye disease. The company did not disclose existing share capital, dilution percentage, or placee details.
Investing in clinical-stage biotech companies like Cambium Bio carries inherent risks linked to clinical trial outcomes, regulatory approvals, and market competition. While advancing Elate Ocular® to phase 3 is a positive development, there is no guarantee of trial success, regulatory clearance, or commercial viability. The company has not provided information on its financial runway post-raise or future capital needs and timelines for potential cash flow generation.
